Podcasts about thoracic surgeons

Dr. Louis Perrault, president of the Association of Cardiovascular and Thoracic Surgeons of Quebec

MDJ Script/ Top Stories for June 13th Publish Date:  June 13th    Commercial: From the BG AD Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Friday, June 13th and Happy Birthday to Tim Allen I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal Wellstar Kennestone Achieves Elite National Recognition in Cardiothoracic Surgery Trio Accused of Trafficking Over 4 Pounds of Meth in Smyrna Marietta Adopts $428M Budget with Staff Raises, Flat Millage Plus, Leah McGrath from Ingles Markets on sodas All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: TOP TECH MECHANICAL STORY 1: Wellstar Kennestone Achieves Elite National Recognition in Cardiothoracic Surgery Wellstar Kennestone Regional Medical Center has earned the highest three-star rating in four cardiac care categories from the Society of Thoracic Surgeons, placing it among the top cardiac surgery programs in the U.S. and Canada. The ratings, based on patient outcomes from 2022-2024, recognize excellence in procedures like CABG (open-heart surgery), Aortic Valve Replacement, and combined surgeries. This achievement highlights Wellstar’s clinical excellence, multidisciplinary teamwork, and patient-centered care. With over 110 cardiologists and surgeons, Wellstar Kennestone is a leader in cardiovascular care and the first in Georgia to earn Comprehensive Cardiac Care Certification. STORY 2: Trio Accused of Trafficking Over 4 Pounds of Meth in Smyrna Haley Noelle Mitchell, John David Moses, and Craig Myers were arrested on June 3 in Smyrna for allegedly trafficking 4.44 pounds of methamphetamine found in a black Infiniti FX35 during a search. Mitchell also faces charges for failing to stop at a stop sign and having an obstructed license plate. All three are charged with drug trafficking and remain in custody without bond at the Cobb County Adult Detention Center. Moses also has a detainer hold. STORY 3: Marietta Adopts $428M Budget with Staff Raises, Flat Millage The Marietta City Council approved a $428 million budget for fiscal year 2026, maintaining a flat millage rate of 4.692 mills for the 24th consecutive year. The budget, up 1.78% from last year, includes a 4% employee raise (pending economic conditions) and funds 812 employees, adding two positions to save costs on downtown sanitation. Public safety remains a priority, with 52% of the general fund allocated to police and fire services. Despite rising costs and flat revenue, the city avoided service cuts. A 3.5% wastewater rate increase will take effect July 1 due to higher treatment costs. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  Break: Ingles Markets 4 STORY 4: Marietta Water Bills to Increase Starting July 1 Starting July 1, Marietta residents will see a 3.5% wastewater rate increase on their water bills, adding about $1.25 per month for the average household. The city attributes the hike to rising costs from the Cobb County Water System for wastewater treatment, infrastructure maintenance, and regulatory compliance. Officials emphasized their commitment to keeping rates low while maintaining reliable, high-quality service. For more details, residents can contact Marietta Power and Water’s customer service. STORY 5: OUT AND ABOUT: 5 Things to Do This Weekend in Cobb County — June 13 - 15 This weekend offers a variety of events in Cobb County! Sparkles Family Fun Center in Kennesaw hosts a skating night with the Peach State Roller Derby team on Friday, including free skate rentals, laser tag, and playground access with $15 admission. Cobb County PARKS kicks off its free "Scene on the Green" series Friday night in Marietta with live music and a performance of *Beetlejuice Jr.*. Acworth Arts Alliance’s "Dreaming" exhibit reception is Saturday, showcasing storytelling art. The Strand Theatre continues its run of *Grease* through June 22, and Mableton’s Riverside EpiCenter Farmers Market on Sunday features 40+ vendors, music, and entertainment. Break: And now here is Leah McGrath from Ingles Markets on sodas We’ll have closing comments after this. Break: TIDWELL TREES Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com tidwelltrees.com toptechmech.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

In April, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule for the fiscal year 2026 Inpatient Prospective Payment System. This annual regulation introduces several initiatives that will have a direct impact on cardiothoracic surgery. The Society of Thoracic Surgeons is diligently reviewing all the proposed changes. They plan to submit their comments in the coming months to represent the interests of cardiothoracic surgeons and their patients effectively.

It's been one year since University Hospitals' cardiac surgeons began performing heart bypass surgeries with the assistance of a surgical robot known as Da Vinci.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the robotic market. He explores the new FDA approval for the Johnson & Johnson robotic surgical system for clinical trials, the background of Johnson & Johnson MedTech, and the location for this trial. He also discusses the details of TAVR, what we currently know about TAVR, and highlights an article by Steve Bell that discusses his own views on Johnson & Johnson and the robotic market.    Joel also reviews recent JANS articles on The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer, a European multicenter study evaluating the prognosis of peripheral early-stage lung adenocarcinoma patients operated on by segmentectomy or lobectomy, early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis, and the use of hybrid stage I to stratify between single ventricle palliation and biventricular repair.   In addition, Joel explores an off-pump ASD closure with a two-layer patch attached to the right atrium, a repair of Scimitar syndrome in a two-year-old via VRAT, and robotic-assisted carinal reconstruction using cross table ventilation. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer  2.) European Multicentre Study Evaluating the Prognosis of Peripheral Early-Stage Lung Adenocarcinoma Patients Operated on by Segmentectomy or Lobectomy  3.) Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED trial  4.) Use of Hybrid Stage I to Stratify Between Single Ventricle Palliation and Biventricular Repair  CTSNET Content Mentioned  1.) Off-Pump ASD Closure With a Two-Layer Patch Attached to the Right Atrium  2.) Repair of Scimitar Syndrome in a Two-Year-Old Via VRAT: Pitfalls of Intra-atrial Baffle  3.) Robotic-Assisted Carinal Reconstruction Using Cross Table Ventilation—A Novel Surgical Technique  Other Items Mentioned  Why am I so tough on Johnson & Johnson and Medtronic and their surgical robotic programs?  CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

For patients with AFib, left atrial appendage (LAA) occlusion should now be part of any non-emergency cardiac operation, and surgical ablation should also be considered. Panayotis Vardas, M.D., discusses how he and colleagues from the Society of Thoracic Surgeons arrived at stronger recommendations for these procedures in their 2023 guidelines. Learn more about related surgical procedures for AFib and the directions of future research.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System for lung cancer. The new edition will be published in January 2025 and has some important changes that reflect an evolving understanding of the disease and more rigorous analysis of data from around the world. Guest: Dr. Valerie Rusch is a Thoracic Surgeon from Memorial Sloan Kettering Cancer CenterMSKCC where she is Vice Chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers. She has held many leadership positions in the American College of Surgeons and other organizations and was part of the team to first described EGFR mutations. She has been chair of the Thoracic Committee for the American Joint Committee on Cancer 6th, 7th, 8th, and now 9th Editions of the Cancer Staging Handbook Guest: Dr. Hisao Asamura is a Professor of Surgery, Chief of Division of Thoracic Surgery at Keio University School of Medicine in Tokyo, Japan and Vice President of the Japan Lung Cancer Society. For IASLC, he is the Chair of the Staging and Prognostic Factors Committee, former Executive Board Director, and Congress President for the 18th World Conference on Lung Cancer. Guest: Dr. Enrico Ruffini is a Thoracic Surgeon and Professor of Thoracic Surgery from the University of Torino, Italy where he is the Chief of the Thoracic Surgery Unit and Director of the Thoracic Surgery Residency Program. He is heavily involved in the European Society of Thoracic Surgeons and Chair of the IASLC Staging and Prognostic Factors Committee – Thymic domain.

SEND US A TEXT MESSAGE!!! Let Drs. Nii & Renee know what you think about the show!SEND US A TEXT MESSAGE!!! Let Drs. Nii & Renee know what you think about the show!Drs. Nii and Renée come together to discuss a recent study published by Health Affairs that contrasts the lack of diversity among US physicians to the impact of debt on the populations that are underrepresented in medicine. The study asserts that understanding the differential burden of debt by race and ethnicity may help to determine strategies to address the lack of diversity, including scholarships, debt relief and financial guidance. Things to expect in this episode:Nii & Renee's micro and macro habits, plus motivation vs. systemsNii checks in with his mentee, and the role significant others play in career plans Outgoing surgeon from the Society of Thoracic Surgeons attacks affirmative action in presentationThe oftentimes prohibitive financial investment of going to medical school, including applying to and being dismissed fromMedical student, devastated by her total medical school debt, posts on InstagramInternational Healthcare Volunteers: ihcv.orgHealth Affairs article, Differences in Debt Among Postgraduate Medical Residents by Self-Designated Race and Ethnicity, 2014-2019WE WANT TO HEAR FROM YOU!!!!TELL US WHAT YOU WANT TO HEAR ON FUTURE EPISODES!!!!FILL OUT THE DOCS OUTSIDE THE BOX PODCAST SURVEY (in partnership w INCROWD)INCROWDMAKE EXTRA MONEY AS A RESIDENT OR ATTENDING - COMPLETE MEDICAL SURVEYS WITH INCROWDWATCH THIS EPISODE ON YOUTUBE!Join our communityText word PODCAST to 833-230-2860Twitter: @drniidarkoInstagram: @drniidarkoEmail: team@drniidarko.comPodcasting Course: www.docswhopodcast.comMerch: https://docs-outside-the-box.creator-spring.comThis episode is edited by:Your Podcast PalThis episode is sponsored byLocumstory. Learn how locum tenens helps doctors make more and have the lifestyle they deserve!. Check them out HERE!

Dr. Yugal K MISHRA is one of India's most well-known and skilled cardiac surgeon. He is Chief of Cardiac Services, Chairman & Chief Cardio Vascular Surgeon at Manipal Hospitals. He is also President of the Society of Minimally Invasive Cardiovascular Surgeons of India, President of the India Association of Cardiovascular & Thoracic Surgeons and Council Member of the Association of Thoracic & Cardiovascular Surgeons of Asia.  Dr Mishra is one of the renowned Robotic & Minimally Invasive Heart Surgeons in Asia. He has performed more than 500 robotic cases in India. Some facts about him : He has over 30 years of experience. He has done more than 20 000 successful procedures He has written more than 200 scientific research papers He has trained more than 100 cardiac surgeons  In this episode, Dr. Yugal Mishra explains the benefits and challenges of Minimally Invasive Cardiac Surgery (MICS) compared to traditional open-heart surgery in India. Dr. Mishra highlights that while MICS offers advantages and that MICS is more expensive due to the advanced equipment and expertise required, but it can ultimately be more cost-effective by reducing hospital stays and enabling patients to return to work sooner. Dr. Mishra discusses the technical challenges, including managing complications and the importance of advanced technology in improving surgical outcomes.  LinkedIn Profile : Yugal Mishra Dr. Mishra Website : https://dryugalmishra.com/   In this episode, Dr. Yugal Mishra explains the benefits and challenges of Minimally Invasive Cardiac Surgery (MICS) compared to traditional open-heart surgery. Dr. Mishra highlights that while MICS offers advantages and that MICS is more expensive due to the advanced equipment and expertise required, but it can ultimately be more cost-effective by reducing hospital stays and enabling patients to return to work sooner. Dr. Mishra discusses the technical challenges, including managing complications, and the importance of advanced technology in improving surgical outcomes.    About Behind the OR Behind the OR is the official podcast channel by Peters Surgical. Here, we invite you to step into the world of surgery, where we uncover what happens behind the closed doors of the operating room and beyond. Each episode features in-depth conversations with expert surgeons, providing insights into the latest surgical techniques, innovations, and the daily lives of those who dedicate themselves to saving lives. Founded in 1926, Peters Surgical is a French company with a global presence in over 90 countries. As a reference group for surgical practices worldwide, we are dedicated to improving surgical outcomes through innovative medical devices, including surgical sutures, hemostatic clips, and surgical glue. Our expertise lies in designing, manufacturing, and distributing these devices.  Visit our website here : https://peters-surgical.com/

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Steven Walker (Academic Respiratory Unit, Southmead Hospital, Bristol, UK) about the joint European Respiratory Society/European Association for Cardio-Thoracic Surgery/European Society of Thoracic Surgeons clinical practice guidelines on adults with spontaneous pneumothorax.

The Accelerators (Drs. Matt Spraker and Simul Parikh) host the lung cancer legend, Brendon Stiles, MD. He is a Professor of Oncology, Medicine, and Thoracic Surgery at Montfiore and Albert Einstein College of Medicine.We discuss all things lung cancer: early stage, locally advanced, staging, quality, and more.The episode is capped with Simul's Lighting Round. Good luck Brendon!We hope you enjoy this #MedEd instant classic!Here are (almost?) all the studies and materials we mentioned during the show:Brendon's "Old Slide" on patient selection and operabilityLobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer (CALGB 140503)Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer (I-SABR)Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials (STARS-ROSEL)Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer (MISSILE)Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic (SABR-BRIDGE)Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerPhase II Study of Accelerated High-Dose Radiation Therapy with Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer (RTOG 0239)Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer (RTOG 0839)Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816)Pacific-2 Press Release, AstraZenecaStudy of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer (MDT-BRIDGE, in progress)Society of Thoracic Surgeons quality initiativesThe Accelerators Podcast is a production of Photon Media, a division of Cold Light Legacy Company.If you'd like to support our efforts, please visit the Cold Light Legacy Company to learn more.

In this episode of Run with Fitpage, we have one of the top Heart Surgeons in the country, Dr Adil Sadiq. Vikas and Dr Adil dive deep into some of the most prominent reasons behind Coronary Artery Disease and ways to prevention.Dr Adil Sadiq is a renowned cardiac surgeon in Bangalore with over 4500 cardiac surgeries, 1600 thoracic procedures, and 65 heart and lung transplants under his belt. He is one of the few surgeons in India who is trained in robotic cardiac surgery and has extensive experience in minimally invasive cardiac surgery. He is currently the Senior Consultant and Head of Cardiothoracic and Vascular Surgery at Sakra World Hospital in Bangalore.Dr Sadiq completed his undergraduate medical degree from Bangalore Medical College and his master's degree in general surgery from Kasturba Medical College, Manipal. He then went on to pursue his super-specialty training in cardiothoracic and vascular surgery at the prestigious Sree Chitra Institute. Dr Sadiq is a highly skilled and experienced cardiac surgeon who is passionate about providing his patients with the best possible care. He is a member of several professional organizations, including the American College of Surgeons and the Society of Thoracic Surgeons. He is also a recipient of several awards, including the "Service Excellence in Cardiovascular Surgery" award from the Times Health Excellence 2018 event.Reach out Dr Adil here: sakraworldhospital.com/doctors/dr-adil-sadiq-institute-of-cardiac-sciences/11About the hostVikas hosts this weekly podcast and enjoys nerding over-exercise physiology, nutrition, and endurance sport in general.  He aims to get people to get out and 'move'.  When he is not working, he is found running, almost always.  He can be found on nearly all social media channels but Instagram is preferred:)Reach out to Vikas:Instagram: @vikas_singhhLinkedIn: Vikas SinghTwitter: @vikashsingh1010Download Fitpage App: fitpage.in/the-all-new-fitpage-app/Subscribe To Our Newsletter For Weekly Nuggets of Knowledge!

In this episode of CTSNet's flagship podcast, editor in chief Joel Dunning is joined by new senior editor of congenital content, Dr. Sameh Said. Together, they run through the latest, most popular content on ctsnet.org—the largest online community of CT surgeons and source of CT surgery information—and breaking cardiothoracic surgery news and research from around the world. After a short introduction, Joel and Sameh begin their discussion on outcomes of pulmonary atresia in neonates, surgical outcomes for type A thoracic aorta dissection, and disparities in access to thoracic surgeons for esophagectomy. They also talk about a new method for VSD closure without ventriculotomy, a double valve replacement from Medtronic, and an anomalous origin of the coronary artery repair from Dr. Said himself. After discussing upcoming events in the CT surgery world, they close with a shoutout to Patrick Myers. JANS Items Mentioned Procedural Outcomes of Pulmonary Atresia with Intact Ventricular Septum in Neonates: A Multicenter Study    Surgical Outcomes of Thoracic Endovascular Aortic Repair for Retrograde Stanford Type A Dissection   Racial, Socioeconomic Disparities Affect Access to Thoracic Surgeons for Esophagectomy  CTSNet Content Mentioned Postinfarction Ventricular Septal Defect Closure Without Ventriculotomy—A Novel Method Medtronic Sponsored Content: Double Valve Replacement—How I Do It Anomalous Aortic Origin of the Right Coronary Artery from the Wrong Sinus of Valsalva (AAORCA): Two Surgical Strategies Other Items Mentioned Uniportal VATS-RATS Training Program at Shanghai Pulmonary Hospital CTSNet Events Calendar

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient's tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Drs. Nii and Renée come together to discuss a recent study published by Health Affairs that contrasts the lack of diversity among US physicians to the impact of debt on the populations that are underrepresented in medicine. The study asserts that understanding the differential burden of debt by race and ethnicity may help to determine strategies to address the lack of diversity, including scholarships, debt relief and financial guidance. Things to expect in this episode:Nii & Renee's micro and macro habits, plus motivation vs. systemsNii checks in with his mentee, and the role significant others play in career plans Outgoing surgeon from the Society of Thoracic Surgeons attacks affirmative action in presentationThe oftentimes prohibitive financial investment of going to medical school, including applying to and being dismissed fromMedical student, devastated by her total medical school debt, posts on InstagramInternational Healthcare Volunteers: ihcv.orgHealth Affairs article, Differences in Debt Among Postgraduate Medical Residents by Self-Designated Race and Ethnicity, 2014-2019WE WANT TO HEAR FROM YOU!!!! TELL US WHAT YOU WANT TO HEAR ON FUTURE EPISODES!!!!FILL OUT THE DOCS OUTSIDE THE BOX PODCAST SURVEY (in partnership w INCROWD)INCROWDMAKE EXTRA MONEY AS A RESIDENT OR ATTENDING - COMPLETE MEDICAL SURVEYS WITH INCROWDWATCH THIS EPISODE ON YOUTUBE!Join our communityText word PODCAST to 833-230-2860Twitter: @drniidarkoInstagram: @drniidarkoEmail: team@drniidarko.comPodcasting Course: www.docswhopodcast.comMerch: https://docs-outside-the-box.creator-spring.comThis episode is edited by:Your Podcast PalThis episode is sponsored by Locumstory. Learn how locum tenens helps doctors make more and have the lifestyle they deserve!. Check them out HERE!

David Tom Cooke, MD, Founding Chief of the Division of General Thoracic Surgery at UC Davis, joins the first episode of 2023 to discuss his colleague's specific role in lung cancer screening and intervention, advances to minimally invasive, robotic and bronchoscopic techniques, and evolving strategies in individualized patient care. Episode Highlights 0:14 Intro 1:52 Introducing David T. Cooke, MD 3:23 The role of thoracic surgeons in improving lung cancer screening rates 6:22 Shared decision making in thoracic surgery 8:16 Lobar, wedge resection or segmentectomy? Plus, robotic techniques? 12:22 PET/CT scans in the staging process 13:52 The surgeon approach to stage IV lung cancer 16:02 Patient follow-up—improved mortality and longer life expectancy 18:50 Prioritizing surgery and neoadjuvant therapy regimens 20:48 Thoracic surgeon role in palliative care 22:57 What's on the horizon in the field: robotic surgery 24:17 Outro Check out other lung cancer episodes of Lungcast: Innovations in Interventional Pulmonology with Dr. Carla Lamb  Lung Cancer Screening: Trials, Tribulations & Triumphs with Dr. James Mulshine Future of Lung Cancer Precision Medicine with Andrea Mazzochi Get More From Lungcast Lungcast on HCPLive: https://www.hcplive.com/podcasts/lungcast Lungcast on American Lung Association: https://www.lung.org/professional-education/lungcast Spotify: https://spoti.fi/3YEDxKw Apple Podcasts: http://bit.ly/3jCVevq YouTube: https://www.youtube.com/@Lungcast/videos

What are warning signs a doctor may be experiencing doctor burnout? How are some nonprofits affected by doctor burnout? What can members of the CHD community do to try to reduce doctor burnout? Today's program is 'Dr. John Calhoon on Doctor Burnout in the CHD Community' and our Guest is Dr. John Calhoon.Dr. Calhoon is both a congenital and adult cardiac surgeon and was my Heart Warrior's surgeon. He also wrote the Foreword for my first book: “Hypoplastic Left Heart Syndrome: A Parent's Handbook.”Dr. Calhoon is the Professor and Founding Chair of the Department of Cardiothoracic Surgery at the University of Texas Health Science Center and also is the Director of the Congenital Heart Center in San Antonio, a partnership of UHS and UTH. Over the years, his interests and expertise have included complex congenital heart surgery; heart and lung transplantation; less invasive cardiac surgery, and improving education and patient care.He has served as the President of many national cardiac associations and is currently President of the Society of Thoracic Surgeons – the largest heart and lung specialty organization in the world., He helped found HeartGift San Antonio, an organization that sponsors charitable lifesaving congenital heart repairs on kids from around the globe. Dr. Calhoon is married to his wife Sarah, and together they have four children: Satchel, Stetson, Seve, and James.Today we'll learn about Dr. Calhoon's views on doctor burnout, some of the causes of doctor burnout, and what the CHD community can do to help prevent or curb doctor burnout.Here's a link to an article about Chip Oswalt – the surgeon who founded HeartGift - Austin: https://ctvstexas.com/a-doctor/Support the showAnna's Buzzsprout Affiliate LinkBaby Blue Sound CollectiveSocial Media Pages:Apple PodcastsFacebookInstagramMeWeTwit...

Patient acuity is a critical benchmark for ensuring the patient has a proper care plan – it essentially saves lives. On MedAxiom HeartTalk, host Melanie Lawson talks with Amy Simone, PA-C, FACC, director of the Marcus Heart Valve Center at Piedmont Heart Institute, and Vinod Thourani, MD, FACC, professor of Cardiac Surgery and chief of Cardiovascular Surgery at Piedmont Healthcare at the Marcus Heart Valve Center. They discuss the challenges of accurately capturing patient acuity in heart failure patients and share innovative solutions to this problem. Guest BiosVinod Thourani, MD, FACC, Professor of Cardiac Surgery, Chief of Cardiovascular Surgery, Piedmont Healthcare at the Marcus Heart Valve Center - Dr. Thourani is board certified in surgery and cardiothoracic surgery. He earned his medical degree from Emory University School of Medicine. Dr. Thourani completed a general surgery internship at Emory University, followed by a residency and fellowship at Emory University. He also completed visiting fellowships for minimally invasive and transcatheter valve surgery at Fuwai Hospital in Beijing, China, and a fellowship with Prof Fred Mohr in Leipzig, Germany. Dr. Thourani is a member of the American Association for Thoracic Surgery, American Board of Thoracic Surgery, American College of Cardiology, American Heart Association, the Heart Valve Society, the International Society of Minimally Invasive Cardiothoracic Surgery, the South Atlantic Cardiovascular Society, and the Society of Thoracic Surgeons. He serves as the President of the Southern Thoracic Surgical Association (2019-2020) and the President-elect for the Heart Valve Society (2019-2020). Dr. Thourani specializes in valve surgery, specifically in minimally invasive and transcatheter aortic and mitral valve surgery. He is passionate about working with a multi-disciplinary team in providing the patient with options for traditional, minimally invasive, and transcatheter surgical options. In his spare time, Dr. Thourani enjoys spending time with his family, traveling, tennis, and going to sporting events and concerts. Amy Simone, PA-C, FACC, Director of the Marcus Heart Valve Center, Piedmont Heart Institute - Amy Simone is a Physician Assistant who received her training in Boston, MA at Massachusetts College of Pharmacy and Health Sciences. She is entering her seventeenth year of practice as a PA, and has spent over a decade in the Structural Heart arena. She served as the Structural Heart and Valve Coordinator at Emory University Midtown Hospital for over 6 years before transitioning to the Piedmont Heart Institute as the Director of the Marcus Heart Valve Center in 2017. She is a Past President of the Academy of Physician Associates in Cardiology (APAC) and in 2022 was appointed the APAC Structural Heart Disease Committee Chair. She is a Fellow of the American College of Cardiology (FACC) and serves on the ACC Cardiovascular Team Section Leadership Council, the ACC Physician Assistant Committee and the ACC Georgia Chapter Program Committee. In 2019 she co-published a textbook entitled Transcatheter Aortic Valve Replacement Program Development – A Guide for the Heart Team. She is passionate about patient advocacy and experience, program optimization, and addressing disparities in care. She lives in Atlanta, GA with her husband Michael and daughter Ivy.

Intro: Dr. Thomas Varghese Jr. is the Associate Chief Medical Quality Officer and Chief Value Officer at the Huntsman Cancer Institute, and Chief of General Thoracic Surgery at the University of Utah. Dr. Varghese is a national leader in minimally invasive applications for general thoracic surgery, recognized by Castle Connolly as one of America's “Top Docs”, and is ranked in the top 10% of the nation by Press Ganey for patient satisfaction scores. His research interests bridge the world of Educational Research and Health Services Research, specifically in the arena of optimizing performance at the patient, surgeon and system levels. He created the Strong for Surgery program, which is now a formal Quality Improvement program of the American College of Surgeons, and active at 331 clinical sites across the nation and 3 state surgical collaboratives.Dr. Varghese holds national leadership positions in the Society of Thoracic Surgeons, Thoracic Surgery Directors Association, American College of Surgeons, and the Society of University Surgeons. Dr. Varghese is active on social media and is the Deputy Editor of Digital Media and Digital Scholarship for the Annals of Thoracic Surgery.Questions We Asked: Where did your passion for leadership come from? Who were your mentors and what made that relationship special? Have you found your mentors formally or informally? How can you create a good formalized mentorship program? How do mentors effectively help their mentees find their career path? How do you create a good mentor/mentee relationship? How can those in the majority be allies to minority groups in medicine and science? How do you be comfortable saying “I don't know”? Quotes & Ideas: “Never stop looking for best practices” You can and should have different mentors for the various areas of your life (academic, career, social, spiritual, etc.) “Mentorship is someone with a particular knowledge or skills that shares them with someone else who does not have it on their own.” “A mentor does not always have to be older than you.” Identify OKR (objectives and key results) and set a time deadline for it “An ally is someone who builds a culture of inclusion” and “A leader is someone who betters the culture of those they lead”. Leaders need to be allies. “Are we better today than we were yesterday, and are we going to be better tomorrow than we were today and how do we achieve that.” “Diversity doesn't end because you hire the next diverse faculty. You have to make sure they thrive in their position.” “You don't know, doesn't necessarily mean you don't act.” “MD means make decisions.” “We are living in the greatest time in history.” “Seek your tribe members” Books Suggestions: The 4 Disciplines of Execution by Sean Covey Peter Drucker Start With Why by Simon Sinek Adam Grant 

This is another episode in our AI is Here series, and today, we're focusing on AI in the hospital setting. In this episode, we discuss patient data and being able to guide a patient's treatment journey with artificial intelligence. Our guest is Dr. Kostas Papagiannopoulos. Kostas is an Honorary Senior Lecturer at Leeds University and serves as Thoracic Surgeon for Leeds Teaching Hospitals. He is also a Medical Advisor to several substantial medical device companies and, until recently, was President of the European Society for Thoracic Surgeons. In today's episode, Kostas discusses where he's seeing AI make its way into the hospital setting and some of the critical barriers to adoption, and how leaders should overcome them. This series is brought you to by SambaNova Systems. SambaNova believes that AI is here, and we've partnered with them to bring you leading experts across industries to discuss where AI is making an impact today.

In this episode of Season 2, Dr. David Tom Cooke interviews Dr. Cherie Erkmen, from Temple University in Philadelphia, PA. Dr. Erkmen grew up in Colorado with devoted parents who encouraged and inspired her to consider a career in medicine. Interestingly, her mom was unofficially a “storm chaser;” officially, she was an atmospheric researcher for National Oceanic and Atmospheric Administration who studied how pollution impacts storm patterns and the connection between air pollution and lung cancer. Through her mom, Dr. Erkmen “gained a lot of courage and vicarious experience.” She remembers having only a “vague” idea of being a doctor when she was growing up. However, along with a cheering section of parents and siblings, Dr. Erkmen had the support to “think big.” In this fascinating conversation, she also shares that her dad's battle with lung cancer motivated her to become a cardiothoracic surgeon. An active member of the STS Workforce on Diversity, Equity, and Inclusion, Dr. Erkmen discusses the importance of listening to what the community needs and creative initiatives that she leads through Temple University. “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity.

In this episode, Dr. Tom Varghese interviews Dr. Allan Pickens, a leading thoracic surgeon from Emory University in Atlanta. Listeners will discover interesting personal details such as Dr. Pickens, along with his five siblings, grew up on a farm in a rural Alabama town. That farm is where he began shaping his extraordinary work ethic. With parents who strongly encouraged good grades and required college after high school, Dr. Pickens always made schoolwork a priority. A high performing student, he was recruited in 6th grade to participate in a special program through the Macy Foundation. This is when Dr. Pickens was first inspired to pursue a career in medicine. Eventually he decided on cardiothoracic surgery. “I enjoy the technical components of surgery and the immediate impact on patient care, and I'm fascinated by chest physiology.” Dr. Pickens shares that growing up in rural Alabama did not provide much opportunity for physician mentorship, especially for minorities. “Finding mentors took some work,” he says. Dr. Pickens discusses some of the challenges he's faced, and how these personal experiences motivated him to “want to give back” and “be involved in the educational process” for underrepresented individuals. “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

This week we were joined by Dr. Bill Kent, a cardiac surgeon at the University of Calgary, to talk about minimally invasive techniques in cardiac surgery. We were curious to learn from him where MIS techniques fit in an era of rapid evolution in cardiac surgery and particularly with the advent of new catheter based techniques. Dr. Kent had a number of important insights into the introduction of new technologies in surgery and the challenges associated with trying something new. Links: 1. Minimally invasive cardiac surgery and the importance of qualitative patient-centered metrics to guide innovations. https://www.sciencedirect.com/science/article/pii/S0022522319304507?via%3Dihub Bio: Dr. William Kent is a cardiac surgeon whose practice focuses on valve surgery and mechanical circulatory support. A Fellow of the Royal College of Surgeons of Canada and a member of the International Society for Minimally Invasive Cardiothoracic Surgery, the Society of Thoracic Surgeons, the Canadian Society of Cardiac Surgeons and the American College of Surgeons, Dr. Kent is particularly interested in minimally invasive mitral valve repair and aortic valve surgery, including aortic valve and root repair as well as the Ross procedure. Dr. Kent completed his undergraduate BA and MSc degrees in Neuroscience at Western University before obtaining his MD and FRCSC in General Surgery at Queen's University. He began his Cardiac Surgery training at the University of Alberta and then continued his residency training at the University of Calgary. Dr. Kent then completed a Fellowship in complex valve surgery, transplant and mechanical circulatory support at Northwestern University in Chicago, before joining the Libin Cardiovascular Institute in 2013. His current position is Clinical Assistant Professor in the Section of Cardiac Surgery. He leads the Minimally Invasive Valve Surgery Program and is Surgical Director of the Mechanical Circulatory Support Program.

To wrap up our “Power of Partnerships” series, Dr. Douglas Wood has a conversation about the thoracic surgeon's role in lung cancer with fellow thoracic surgeons Dr. Leah Backhus, Dr. Tom Varghese, and Dr. Farhood Farjah. They discuss the surgeon's role in screening programs, evaluating nodules from a surgical perspective, and how to avoid harm and minimize unnecessary surgery for patients without cancer. Douglas E. Wood, MD, FACS, FRCSEd is the Chair of Surgery at the University of Washington School of Medicine in Seattle, and a physician with the Seattle Care Alliance. Dr. Wood has previously served as president of the Society of Thoracic Surgeons and director of the American Board of Thoracic Surgery. Leah Backhus, MD, MPH, FACS is an Associate Professor of Cardiothoracic Surgery at Stanford University. Dr. Backhus is the Co-Director of the Thoracic Surgery Clinical Research Program and Associate Program Director of the Thoracic CT Surgery Residency Training Program at Stanford. Thomas K. Varghese Jr., MD, MS is an Associate Professor of Surgery and the Head of Thoracic Surgery at the University of Utah. Dr. Varghese has also previously served as the Interim Executive Medical Director at the Huntsman Cancer Institute. Farhood Farjah, MD, MPH, FACS is an Associate Professor of Surgery and an Endowed Chair of Lung Cancer Research at the University of Washington. Dr. Farjah is a physician with the Seattle Cancer Care Alliance. As a follow-up to the National Lung Cancer Roundtable and American College of Radiology's 2021 webinar series, the “Power of Partnerships” limited podcast series will feature conversations currently happening in the world of lung cancer with the people pushing the field into the future. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

In this episode, Dr. David Tom Cooke interviews Dr. Raja Flores, from Mount Sinai in New York City (NYC). With generous detail, Dr. Flores describes his “jagged line” to cardiothoracic surgery, while crediting luck and his supportive mom for much of his success. He shares how he “grew up poor” in NYC with neighborhood friends who turned to drugs and often ended up in jail. For Dr. Flores, though, personal experiences during repeated trips to the emergency room as a kid sparked his interest in medicine. He opens up about his passion for improving lung cancer survival—an area that has “a lot of room for improvement.” Dr. Flores explains that 80% of people living in NYC public housing are living with serious health hazards and exposures, but there is no “political activity” to improve the conditions. This reality fueled Dr. Flores's motivation to launch a run for NYC mayor in 2021. “I wanted to bring awareness and effect change on a greater scale,” he shares. While unsuccessful, his campaign as “a son of New York City and mayor for all people” was organized and run by four medical students. Hear, too, what Dr. Flores says about the cardiothoracic surgery specialty “exploding” in years to come. “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

In this episode—which does not disappoint—Dr. Tom Varghese interviews Dr. Gail Darling, head of surgery at Dalhousie University in Nova Scotia, Canada. Dr. Darling reveals an “ordinary upbringing,” growing up in Canada with an accountant dad and a stay-at-home mom. Interestingly, her 12th grade English teacher was the person who recommended that Dr. Darling think about medicine as a career; before that, she was going to study English. She went on to become the first person in her family to attend university. The original plan was family medicine, but during the surgery rotation, Dr. Darling realized there was more opportunity to “make a difference and make things happen” in surgery. She liked “the pace and the people—birds of a feather.” This “giant” in cardiothoracic surgery shares her perspectives and thoughts about overcoming challenges associated with shattering glass ceilings, constant changes in cardiothoracic surgery, and the need to adopt a growth mindset in the quest for excellence. In reflecting on her career so far, Dr. Darling offers some wise words and sage advice for listeners: “Never give in; Don't be limited by what other people tell you; Think about what drives you, what motivates you, what gets you up in the morning; Don't let anything stand in your way.” “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

Welcome to the first episode of “All Things AFib.” I am your host, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California. For our inaugural episode, I'm thrilled to welcome Dr. James Cox, a legend in the field of cardiothoracic surgery, and inventor of the Cox maze surgery. The world is lucky that Dr. Cox decided to become a surgeon because he also had an offer to play professional baseball with the LA Dodgers. Dr. Cox was the Evarts A. Graham Professor of Surgery, vice-chairman of the department of surgery, and chief of the division of cardiothoracic surgery at Washington University School of Medicine and Barnes Hospital in St. Louis, MO. It was here in 1987 that he developed the eponymous “maze” procedure, which is still the gold standard in the world today. Dr. Cox was the 81st (and youngest) president of the American Association for Thoracic Surgery (AATS), a member of the editorial board of more than 20 scientific journals, and editor-in-chief of two AATS journals. Among the numerous awards and honors he has received throughout his illustrious career, Dr. Cox is the only surgeon to receive the Distinguished Scientist Award from the AATS, the Society of Thoracic Surgeons, and the Heart Rhythm Society. He is the only U.S. cardiac surgeon in the Russian Academy of Medical Sciences. Cox is dedicated to clinical excellence, the development of new techniques, and the training of the next generation of surgeons. Discussion points:What is Atrial Fibrillation (AFib)?The AFib word origins actually meant the appearance of a “sack of worms”The two types of Macro Re-Entry– Automaticity and micro/macro re-entryTreatment methods– Cardiothoracic Surgeons vs. ElectrophysiologistsThe technicalities of terms Maze III vs. Maze IV, the confusion, and even a lawsuitWhat are the confusing statistics around pacemaker implantation and the Cox maze procedure?Post-operative and medicinal damage to the sinus nodeAround 5% of patients may need pacemakers due to “sick” sinus nodes, not AFib surgeryA discussion of Left Atrial Appendage managementIs there a percentage of AFib patients that should have more than the Left Atrial closure procedure?Do we need to get more surgeons to do Left Atrial closure?Discussion of hybrid maze proceduresWill we still be doing maze procedures in 30 years?Imagining tools we may be using in the futureResources:Dr. James Cox Original Papers: The surgical treatment of atrial fibrillation. I. Summary of the current concepts of the mechanisms of atrial flutter and atrial fibrillation. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure.Dr. James Cox LinkedInDr. James Cox Receives Jacobson Innovation Award Dr. Kiankhooy LinkedInAll Things AFib WebsiteAll Things AFib TwitterAll Things AFib YouTube Channel

In this episode, Dr. David Tom Cooke interviews Dr. Jacques Kpodonu, from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. Listeners will discover fascinating personal details, like why Dr. Kpodonu considers himself an “international gentleman.” He was born in Paris, France—his mom's home city, but at 8 years old, moved to his dad's country of Ghana. Throughout his childhood years, the family moved back and forth between the two countries several times. In Ghana, Dr. Kpodonu's dad served as the country's first cardiologist, and today, at 84 years old, he is still practicing medicine—"as active as ever.” After attending medical school at the University of Ghana, Dr. Kpodonu felt a “pull” to complete his training in the US. Why cardiothoracic surgery? His dad's influence pushed him to “do something with the heart.” From an early age, he was reading EKGs for his dad—“making some money on the side.” A staunch advocate for global health equity, Dr. Kpodonu details his work with health care disparities in underserved communities. He also illustrates an exciting future for the specialty and advises young cardiothoracic surgeons to “keep an open mind.” “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

In this episode of Season 2, Dr. Tom Varghese interviews Dr. Joseph Dearani, from the Mayo Clinic in Rochester, MN. Described as a leader extraordinaire, Dr. Dearani reflects on his STS presidency and shares the most challenging aspects of leading the organization during the first 10 months of the COVID-19 pandemic. He says adapting, rebounding, and refocusing were key. Dr. Dearani details captivating personal stories such as how his father's family—who were silk weavers—emigrated from Syria; how his father, as a young boy, shined shoes on a street corner in Patterson, New Jersey, and then used his earnings to buy bread for dinner on the way home; and what it was like growing up with eight younger sisters. His father, who went on the become a family physician, inspired Dr. Dearani to pursue a career in medicine. The decision to specialize in cardiothoracic surgery, though, was a little less straightforward. In fact, surgery wasn't even one of his initial interests. Instead, he considered emergency medicine and primary care. It was when Dr. Dearani rotated onto cardiac surgery toward the end of medical school that he decided he wanted to be heart surgeon. In addition to medicine, Dr. Dearani has a love for music. Listeners will hear how a nun visiting on Thanksgiving convinced him to take saxophone lessons. He continued playing throughout college and eventually the saxophone became a “religious part of my everyday life,” he says. “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

In the first episode of Season 2, Dr. David Tom Cooke interviews Dr. Valerie Rusch, esteemed medical researcher and thoracic surgeon from Memorial Sloan-Kettering Cancer Center in New York City. Dr. Rusch reveals fascinating details about her storied career, excitedly sharing that cardiothoracic surgery is “in a time of wonderful transformation.” She describes growing up in Manhattan with powerful lessons from her mother about being a strong woman. This counsel—along with a summer job as a surgical scrub tech—motivated Dr. Rusch to pursue a career in medicine. She knew it wouldn't be easy, but with persistence and resilience, she carried on and became one of the world's top experts in the management of lung cancer and mesothelioma. Throughout the episode, Dr. Rusch offers valuable advice for young surgeons. “Be nimble and flexible,” she says. In addition, Dr. Rusch explains the importance of being open to new ideas and thoughtful about acquiring new skills to take care of patients. The faces of cardiothoracic surgery are different than they were 30 years ago, which she says, is "a benefit to the specialty, surgery in general, and especially to our patients.” Is the thoracic surgeon of tomorrow different than the thoracic surgeon of today? According to Dr. Rusch, “absolutely.” “Same Surgeon, Different Light” is a program from The Society of Thoracic Surgeons designed to demystify cardiothoracic surgery, revealing the men and women behind their surgical masks. Learn more about STS diversity and inclusion efforts at sts.org/diversity. Patients can learn more about cardiothoracic diseases and their treatments at ctsurgerypatients.org.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

This episode features Dr. Abe DeAnda, MD, FACS. He attended medical school, residency, and fellowship training at Stanford University in California. He currently serves as a professor and chief of cardiovascular and thoracic surgery at UTMB.In this episode, we get a look at the first fellowship to be featured on the show! Tune in to learn all the ways to become a cardiac surgeon as well as tips on how to do so!RESOURCES:American Board of Thoracic Surgery (https://www.abts.org/)CTSNet (https://www.ctsnet.org/)American Association for Thoracic Surgeons (https://www.aats.org/aatsimis/AATSWeb)Society of Thoracic Surgeons (https://www.sts.org/)Western Thoracic Surgical Association (https://westernthoracic.org/)Southern Thoracic Surgical Association (https://stsa.org/)Dr. DeAnda: abdeanda@utmb.eduMe: atmeffor@utmb.edu